Institut De Recherches Internationales Servier IRIS — Sponsor Intelligence | 30 EU Trials

Filter these 30 trials by condition, phase, country and more.

Open in Search →

30 Registered trials

7 Recruiting

22 Completed trials

19 Countries active

39 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (Other)

Phase I (FiH)

Other

Phase III: 7 Phase I/II: 4 Phase I: 2 Phase I (Other): 5 Phase I (FiH): 6 Other: 6

Oversight events:

11 temporary halts 1 urgent safety measure 1 unexpected event across 4 trials

View oversight register →

100%

22 of 22 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioma 2 Type 2 diabetes mellitus 2 Non-small cell lung cancer metastatic 1 Acute myeloid leukaemia recurrent 1 Chronic myelomonocytic leukaemia 1 Gastric cancer 1 Non-small cell lung cancer 1 Chondrosarcoma 1 Myelodysplastic syndrome transformation 1 Cholangiocarcinoma 1 Epileptic encephalopathy 1 Myelodysplastic syndrome 1

Top IMPs

IVOSIDENIB 4 AZACITIDINE 3 GEMCITABINE 2 GLICLAZIDE 2 SYM025 2 VORASIDENIB 2 4-{[(3S)-2-(4-CHLORO-2-{4-[(5-CYANO-1,2-DIMETHYL-1H-PYRROL-3-YL)(4-HYDROXYPHENYL)CARBAMOYL]-1,5-DIMETHYL-1H-PYRROL-2-YL}BENZOYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHYL}MORPHOLIN-4-IUM HYDROGEN SULFATE 1 ALLOGENEIC T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR TARGETING CD19, WITH THE GENES TRAC AND CD52 DISRUPTED 1 ALLOPURINOL 1 BEVACIZUMAB 1 CAPECITABINE 1 CEMIPLIMAB 1

All trials

30 total

A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19 Pending

2026-526212-37-00 Phase III 1 country ALLOGENEIC T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR TARGETING CD19, WITH T…
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment Recruiting

2024-517923-38-00 Phase I (Other) 2 countries
Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE… Recruiting

2024-516180-85-00 Phase III 4 countries BEVACIZUMAB; CAPECITABINE; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Recruiting

2025-523474-16-00 Phase I (FiH) 4 countries CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN HYDROCHLORIDE TRI…
A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study of S230815 in paediatric participants with KCNT1-relate… Recruiting

2024-513332-17-00 Phase I (FiH) 3 countries S230815-2
A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A… Recruiting

2023-510155-37-00 Phase III 5 countries AZACITIDINE; IVOSIDENIB
Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste… Recruiting

2023-508507-20-00 Phase III 7 countries IVOSIDENIB
A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignac… Recruiting

2024-511344-11-00 Phase I 1 country
Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One F… Ended

2026-526040-13-00 1 country
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapa… Ended

2026-525823-26-00 1 country
A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP Ended

2025-521249-25-00 Phase I (FiH) 5 countries S095035; TNG462
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarc… Ended

2024-514261-19-00 Phase I/II 3 countries CISPLATIN; DURVALUMAB; GEMCITABINE; IVOSIDENIB
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended

2024-513738-39-00 Phase I/II 6 countries TEMOZOLOMIDE; VORASIDENIB
A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended

2023-507995-33-00 Phase I/II 7 countries PEMBROLIZUMAB; SYM025
Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended

2024-512961-15-00 Phase III 5 countries VORASIDENIB
A Phase 3 study to test the AG-120 in combination with Azacitidine in comparison with the use of Azacitidine alone in patients ≥ 18 Years of… Ended

2024-514309-73-00 Phase III 5 countries AZACITIDINE; IVOSIDENIB
A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic … Ended

2024-511380-29-00 Phase I (Other) 1 country
A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted

2023-508730-34-00 Phase I/II 7 countries CEMIPLIMAB; SYM023; SYM024; SYM025
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy P… Ended

2024-519567-18-00 1 country
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant… Ended

2024-519470-39-00 1 country
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant… Ended

2024-519250-37-00 1 country
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® M… Ended

2024-519640-32-00 1 country
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended

2024-514356-33-00 Phase I (FiH) 3 countries ALLOPURINOL; RASBURICASE; S227928; VENETOCLAX
Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (Hig… Ended

2024-514298-23-00 Phase I (Other) 1 country

Showing 1–24 of 30 trials

← All sponsors A–Z